Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group

Elise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, Nelly Firmin, Antoine Italiano, Nicolas Isambert, Jean Emmanuel Kurtz, Corinne Delcambre, Valérie Lebrun, Pauline Soibinet-Oudot, Christine Chevreau, Emmanuelle Bompas, Christine Le Maignan, Pascaline Boudou-Rouquette, Axel Le Cesne, Julien Mancini, Jean Yves Blay, Florence Duffaud

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    10 Citations (Scopus)

    Résumé

    Treatment options for metastatic osteosarcomas are scarce. Following failure of standard first line therapy, patients who relapse present a challenging treatment dilemma, and have a poor prognosis. Surgical removal of all metastases is essential. A retrospective analysis of patients with metastatic osteosarcomas was conducted in 15 French Sarcoma Group centers. From January 2009 to December 2018, we identified 120 adult patients; 36 with synchronous and 84 with metachronous metastases with 74 males and 46 females. Mean age was 30 years (18-53). Metastatic sites were lung, bone and other in 91, 11 and 24 patients, respectively. Mean time to first metachronous metastases was 22 months (4-97). All patients except 13 (10.8%) with metachronous metastases received a first line systemic treatment for relapse, and 39 patients (32.5%) were included in a clinical trial. Eighty-one patients (67.5%) had local treatment of distant metastases. Median progression free survival (PFS) and overall survival (OS) were 5.5 (95% CI 4.6-6.4) and 20.5 months (95% CI 13.2-27.7) respectively for the overall group. In multivariate analysis, more than five metastases, time to first metastases <24 months, were statistically significant negative prognostic factors for OS and PFS (P =.002, ≤.001 and P =.006, ≤.001, respectively). Surgery of metastases was associated with better prognosis on OS and PFS (P =.001 and.037, respectively). The presence of bone metastases was a negative prognostic factor on OS but not on PFS (P =.021). In reference sarcoma centers, relapsed osteosarcoma patients with more than one metastasis commonly receive more than one line of systemic therapy, and are included in clinical trial if available.

    langue originaleAnglais
    Pages (de - à)645-653
    Nombre de pages9
    journalInternational Journal of Cancer
    Volume150
    Numéro de publication4
    Les DOIs
    étatPublié - 15 févr. 2022

    Contient cette citation